86 related articles for article (PubMed ID: 35786978)
1. Capecitabine: Still a Standard Option in the Adjuvant Setting of Biliary Tract Cancer?
Edeline J; Malka D
J Clin Oncol; 2022 Nov; 40(31):3667-3668. PubMed ID: 35786978
[No Abstract] [Full Text] [Related]
2. Capecitabine Extends Survival for Biliary Tract Cancer.
Cancer Discov; 2017 Jul; 7(7):OF1. PubMed ID: 28572460
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant and neoadjuvant chemotherapy for biliary tract cancer: a review of randomized controlled trials.
Nakachi K; Gotohda N; Hatano E; Nara S; Takahashi S; Kawamoto Y; Ueno M
Jpn J Clin Oncol; 2023 Nov; 53(11):1019-1026. PubMed ID: 37599063
[TBL] [Abstract][Full Text] [Related]
4. BILCAP trial and adjuvant capecitabine in resectable biliary tract cancer: reflections on a standard of care.
Rizzo A; Brandi G
Expert Rev Gastroenterol Hepatol; 2021 May; 15(5):483-485. PubMed ID: 33307876
[TBL] [Abstract][Full Text] [Related]
5. Advances in adjuvant therapy of biliary tract cancer: an overview of current clinical evidence based on phase II and III trials.
Belkouz A; Wilmink JW; Haj Mohammad N; Hagendoorn J; de Vos-Geelen J; Dejong CHC; Homs MYV; Groot Koerkamp B; van Gulik TM; van Oijen MGH; Punt CJA; Klümpen H
Crit Rev Oncol Hematol; 2020 Jul; 151():102975. PubMed ID: 32464483
[TBL] [Abstract][Full Text] [Related]
6. Reevaluating Adjuvant Capecitabine for Resected Biliary Tract Cancer.
Benjamin DJ; Prasad V
Oncologist; 2024 Feb; 29(2):100-101. PubMed ID: 37682029
[TBL] [Abstract][Full Text] [Related]
7. Capecitabine with/without mitomycin C: results of a randomized phase II trial of second-line therapy in advanced biliary tract adenocarcinoma.
Cereda S; Milella M; Cordio S; Leone F; Aprile G; Galiano A; Mosconi S; Vasile E; Santini D; Belli C; Auriemma A; Novarino A; Vaccaro V; Martines C; Marino D; Lutrino SE; Palazzo V; Reinach B; Aldrighetti L; Reni M
Cancer Chemother Pharmacol; 2016 Jan; 77(1):109-14. PubMed ID: 26659366
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant Capecitabine for Biliary Cancer and the Importance of Looking Beyond P-Values.
Fojo AT; Neugut AI
Oncologist; 2024 Feb; 29(2):102-105. PubMed ID: 37682036
[TBL] [Abstract][Full Text] [Related]
9. Varlitinib plus capecitabine in second-line advanced biliary tract cancer: a randomized, phase II study (TreeTopp).
Javle MM; Oh DY; Ikeda M; Yong WP; Hsu K; Lindmark B; McIntyre N; Firth C
ESMO Open; 2022 Feb; 7(1):100314. PubMed ID: 34922298
[TBL] [Abstract][Full Text] [Related]
10. Combination Therapy with Capecitabine and Cisplatin as Second-Line Chemotherapy for Advanced Biliary Tract Cancer.
Jung JH; Lee HS; Jo JH; Cho IR; Chung MJ; Bang S; Park SW; Song SY; Park JY
Chemotherapy; 2017; 62(6):361-366. PubMed ID: 28848173
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant capecitabine in biliary tract cancer: a standard option?
Malka D; Edeline J
Lancet Oncol; 2019 May; 20(5):606-608. PubMed ID: 30922732
[No Abstract] [Full Text] [Related]
12. Adjuvant chemotherapy in biliary tract cancer patients: A systematic review and meta-analysis of randomized controlled trials.
Caparica R; Bruzzone M; Hachem GE; Ceppi M; Lambertini M; Glasberg J; de Azambuja E; Van Laethem JL; Hendlisz A
Crit Rev Oncol Hematol; 2020 May; 149():102940. PubMed ID: 32252001
[TBL] [Abstract][Full Text] [Related]
13. The Landmark Series: Gallbladder Cancer.
Gamboa AC; Maithel SK
Ann Surg Oncol; 2020 Aug; 27(8):2846-2858. PubMed ID: 32474816
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of capecitabine and cisplatin in previously untreated advanced biliary tract cancer.
Hong YS; Lee J; Lee SC; Hwang IG; Choi SH; Heo JS; Park JO; Park YS; Lim HY; Kang WK
Cancer Chemother Pharmacol; 2007 Aug; 60(3):321-8. PubMed ID: 17143602
[TBL] [Abstract][Full Text] [Related]
15. SEOM clinical guidelines for pancreatic and biliary tract cancer (2020).
Gómez-España MA; Montes AF; Garcia-Carbonero R; Mercadé TM; Maurel J; Martín AM; Pazo-Cid R; Vera R; Carrato A; Feliu J
Clin Transl Oncol; 2021 May; 23(5):988-1000. PubMed ID: 33660222
[TBL] [Abstract][Full Text] [Related]
16. Pitfalls, challenges, and updates in adjuvant systemic treatment for resected biliary tract cancer.
Rizzo A; Brandi G
Expert Rev Gastroenterol Hepatol; 2021 May; 15(5):547-554. PubMed ID: 33571059
[No Abstract] [Full Text] [Related]
17. A phase I study of sorafenib, oxaliplatin and 2 days of high dose capecitabine in advanced pancreatic and biliary tract cancer: a Wisconsin oncology network study.
LoConte NK; Holen KD; Schelman WR; Mulkerin DL; Deming DA; Hernan HR; Traynor AM; Goggins T; Groteluschen D; Oettel K; Robinson E; Lubner SJ
Invest New Drugs; 2013 Aug; 31(4):943-8. PubMed ID: 23263993
[TBL] [Abstract][Full Text] [Related]
18. Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial.
Nehls O; Oettle H; Hartmann JT; Hofheinz RD; Hass HG; Horger MS; Koppenhöfer U; Hochhaus A; Stieler J; Trojan J; Gregor M; Klump B
Br J Cancer; 2008 Jan; 98(2):309-15. PubMed ID: 18182984
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant therapy in biliary tract cancers: oral fluoropyrimidine as a beginning.
Chiang NJ; Chen LT
Lancet; 2023 Jan; 401(10372):170-171. PubMed ID: 36681404
[No Abstract] [Full Text] [Related]
20. Role of adjuvant and neoadjuvant therapy for resectable biliary tract cancer.
Nara S; Esaki M; Ban D; Takamoto T; Mizui T; Shimada K
Expert Rev Gastroenterol Hepatol; 2021 May; 15(5):537-545. PubMed ID: 33793366
[No Abstract] [Full Text] [Related]
[Next] [New Search]
